Literature DB >> 15141141

Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women.

Yawei Zhang1, Theodore R Holford, Brian Leaderer, Shelia Hoar Zahm, Peter Boyle, Lindsay McOmber Morton, Bing Zhang, Kaiyong Zou, Stuart Flynn, Giovanni Tallini, Patricia H Owens, Tongzhang Zheng.   

Abstract

OBJECTIVE: To further investigate the role of prior medical conditions and medication use in the etiology of non-Hodgkin lymphoma (NHL), we analyzed the data from a population-based case-control study of NHL in Connecticut women.
METHODS: A total of 601 histologically confirmed incident cases of NHL and 717 population-based controls were included in this study. In-person interviews were administered using standardized, structured questionnaires to collect information on medical conditions and medication use.
RESULTS: An increased risk was found among women who had a history of autoimmune disorders (such as rheumatoid arthritis, lupus erythematosus, Sjogren's syndrome, and multiple sclerosis), anemia, eczema, or psoriasis. An increased risk was also observed among women who had used steroidal anti-inflammatory drugs and tranquilizers. A reduced risk was found for women who had scarlet fever or who had used estrogen replacement therapy, aspirin, medications for non-insulin dependent diabetes, HMG-CoA reductase inhibitors, or beta-adrenergic blocking agents. Risk associated with past medical history appeared to vary based on NHL subtypes, but the results were based on small number of exposed subjects.
CONCLUSION: A relationship between certain prior medical conditions and medication use and risk of NHL was observed in this study. Further studies are warranted to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141141     DOI: 10.1023/B:CACO.0000027506.55846.5d

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  45 in total

1.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

Authors:  Elizabeth A Platz; Srinivasan Yegnasubramanian; Jun O Liu; Curtis R Chong; Joong Sup Shim; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci; William G Nelson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

2.  Self-reported history of infections and the risk of non-Hodgkin lymphoma: an InterLymph pooled analysis.

Authors:  Nikolaus Becker; Michael O Falster; Claire M Vajdic; Silvia de Sanjose; Otoniel Martínez-Maza; Paige M Bracci; Mads Melbye; Karin Ekström Smedby; Eric A Engels; Jennifer Turner; Paolo Vineis; Adele Seniori Costantini; Elizabeth A Holly; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Brian C-H Chiu; Maurizio Montella; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Wendy Cozen; Andrew E Grulich; Robert Newton
Journal:  Int J Cancer       Date:  2012-08-12       Impact factor: 7.396

Review 3.  Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Argirios Tsantes; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

4.  Genotype frequency and F ST analysis of polymorphisms in immunoregulatory genes in Chinese and Caucasian populations.

Authors:  Qing Lan; Min Shen; Dino Garcia-Rossi; Stephen Chanock; Tongzhang Zheng; Sonja I Berndt; Vinita Puri; Guilan Li; Xingzhou He; Robert Welch; Shelia H Zahm; Luoping Zhang; Yawei Zhang; Martyn Smith; Sophia S Wang; Brian C-H Chiu; Martha Linet; Richard Hayes; Nathaniel Rothman; Meredith Yeager
Journal:  Immunogenetics       Date:  2007-10-16       Impact factor: 2.846

5.  Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.

Authors:  Lesley A Anderson; Shahinaz Gadalla; Lindsay M Morton; Ola Landgren; Ruth Pfeiffer; Joan L Warren; Sonja I Berndt; Winnie Ricker; Ruth Parsons; Eric A Engels
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

6.  HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.

Authors:  Chun Chao; Lanfang Xu; Donald I Abrams; William J Towner; Michael A Horberg; Wendy A Leyden; Michael J Silverberg
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

7.  Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study.

Authors:  Brenda M Birmann; Edward L Giovannucci; Bernard A Rosner; Graham A Colditz
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-26

8.  Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition.

Authors:  Laura Costas; Leila Lujan-Barroso; Yolanda Benavente; Naomi E Allen; Pilar Amiano; Eva Ardanaz; Caroline Besson; Heiner Boeing; Bas Bueno-de-Mesquita; Iris Cervenka; Renée T Fortner; Agnès Fournier; Marc Gunter; Sophia Harlid; José María Huerta; Mats Jerkeman; Karin Jirström; Rudolf Kaaks; Anna Karakatsani; Kay-Tee Khaw; Anastasia Kotanidou; Eiliv Lund; Giovanna Masala; Amalia Mattiello; Beatrice Melin; Virginia Menéndez; Neil Murphy; Alexandra Nieters; Kim Overvad; Elio Riboli; Carlotta Sacerdote; Maria-Jose Sánchez; Julie A Schmidt; Sabina Sieri; Anne Tjønneland; Antonia Trichopoulou; Rosario Tumino; Roel Vermeulen; Elisabete Weiderpass; Silvia de Sanjosé; Antonio Agudo; Delphine Casabonne
Journal:  Am J Epidemiol       Date:  2019-02-01       Impact factor: 4.897

9.  Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort.

Authors:  Eva Erber; Unhee Lim; Gertraud Maskarinec; Laurence N Kolonel
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

10.  Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin.

Authors:  Alexis Dumortier; André-Dante Durham; Matteo Di Piazza; Sophie Vauclair; Ute Koch; Gisèle Ferrand; Isabel Ferrero; Shadmehr Demehri; Lynda Li Song; Andrew G Farr; Warren J Leonard; Raphael Kopan; Lucio Miele; Daniel Hohl; Daniela Finke; Freddy Radtke
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.